The DOI matches its Crossref record; 157 of the 157 references it cites were found in a registry or an index.
High-Grade Serous Ovarian Cancer: Basic Sciences, Clinical and Therapeutic Standpoints
Open accessAbstract
Among a litany of malignancies affecting the female reproductive tract, that of the ovary is the most frequently fatal. Moreover, while the steady pace of scientific discovery has fuelled recent ameliorations in the outcomes of many other cancers, the rates of mortality for ovarian cancer have been stagnant since around 1980. Yet despite the grim outlook, progress is being made towards better understanding the fundamental biology of this disease and how its biology in turn influences clinical behaviour. It has long been evident that ovarian cancer is not a unitary disease but rather a multiplicity of distinct malignancies that share a common anatomical site upon presentation. Of these, the high-grade serous subtype predominates in the clinical setting and is responsible for a disproportionate share of the fatalities from all forms of ovarian cancer. This review aims to provide a detailed overview of the clinical-pathological features of ovarian cancer with a particular focus on the high-grade serous subtype. Along with a description of the relevant clinical aspects of this disease, including novel trends in treatment strategies, this text will inform the reader of recent updates to the scientific literature regarding the origin, aetiology and molecular-genetic basis of high-grade serous ovarian cancer (HGSOC).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Rubin, M., & Stephen, C. D. (1993) · Cited by 3,149
Genetic Heterogeneity and Penetrance Analysis of the BRCA1 and BRCA2 Genes in Breast Cancer Families
Ford, D., Easton, D. F., Stratton, M., Narod, S., Goldgar, D., Devilee, P., Bishop, D. T., Weber, B., Lenoir, G., Chang-Claude, J., et al. (1998) · The American Journal of Human Genetics · doi:10.1086/301749 · Cited by 3,037
McGuire, W. P., Hoskins, W. J., Brady, M. F., Kucera, P. R., Partridge, E. E., Look, K. Y., Clarke-Pearson, D. L., & Davidson, M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601043340101 · Cited by 2,796
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
Armstrong, D. K., Bundy, B., Wenzel, L., Huang, H. Q., Baergen, R., Lele, S., Copeland, L. J., Walker, J. L., & Burger, R. A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052985 · Cited by 2,625
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
Vergote, I., Tropé, C. G., Amant, F., Kristensen, G. B., Ehlen, T., Johnson, N., Verheijen, R. H. M., van der Burg, M. E. L., Lacave, A. J., Panici, P. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908806 · Cited by 2,537
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
Mirza, M. R., Monk, B. J., Herrstedt, J., Oza, A. M., Mahner, S., Redondo, A., Fabbro, M., Ledermann, J. A., Lorusso, D., Vergote, I., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611310 · Cited by 2,451
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Burger, R. A., Brady, M. F., Bookman, M. A., Fleming, G. F., Monk, B. J., Huang, H., Mannel, R. S., Homesley, H. D., Fowler, J., Greer, B. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104390 · Cited by 2,404
Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth
Nieman, K. M., Kenny, H. A., Penicka, C. V., Ladanyi, A., Buell-Gutbrod, R., Zillhardt, M. R., Romero, I. L., Carey, M. S., Mills, G. B., Hotamisligil, G. S., et al. (2011) · Nature Medicine · doi:10.1038/nm.2492 · Cited by 2,279
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C., Meier, W., Shapira-Frommer, R., Safra, T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105535 · Cited by 1,883
Pujade-Lauraine, E., Ledermann, J. A., Selle, F., Gebski, V., Penson, R. T., Oza, A. M., Korach, J., Huzarski, T., Poveda, A., Pignata, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30469-2 · Cited by 1,855
Jayson, G. C., Kohn, E. C., Kitchener, H. C., & Ledermann, J. A. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62146-7 · Cited by 1,850
The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory
Kurman, R. J., & Shih, I.-M. (2010) · American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181cf3d79 · Cited by 1,846
Coleman, R. L., Oza, A. M., Lorusso, D., Aghajanian, C., Oaknin, A., Dean, A., Colombo, N., Weberpals, J. I., Clamp, A., Scambia, G., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32440-6 · Cited by 1,693
Ovarian Cancer Development and Metastasis
Lengyel, E. (2010) · The American Journal of Pathology · doi:10.2353/ajpath.2010.100105 · Cited by 1,672
Pujade-Lauraine, E., Hilpert, F., Weber, B., Reuss, A., Poveda, A., Kristensen, G., Sorio, R., Vergote, I., Witteveen, P., Bamias, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.4489 · Cited by 1,622
Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
Tothill, R. W., Tinker, A. V., George, J., Brown, R., Fox, S. B., Lade, S., Johnson, D. S., Trivett, M. K., Etemadmoghadam, D., Locandro, B., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0196 · Cited by 1,467
Rethinking ovarian cancer: recommendations for improving outcomes
Vaughan, S., Coward, J. I., Bast, R. C., Berchuck, A., Berek, J. S., Brenton, J. D., Coukos, G., Crum, C. C., Drapkin, R., Etemadmoghadam, D., et al. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3144 · Cited by 1,464
Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C. L., Meier, W., Shapira-Frommer, R., Safra, T., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70228-1 · Cited by 1,442
Evaluating cell lines as tumour models by comparison of genomic profiles
Domcke, S., Sinha, R., Levine, D. A., Sander, C., & Schultz, N. (2013) · Nature Communications · doi:10.1038/ncomms3126 · Cited by 1,418
Kehoe, S., Hook, J., Nankivell, M., Jayson, G. C., Kitchener, H., Lopes, T., Luesley, D., Perren, T., Bannoo, S., Mascarenhas, M., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)62223-6 · Cited by 1,414
Aghajanian, C., Blank, S. V., Goff, B. A., Judson, P. L., Teneriello, M. G., Husain, A., Sovak, M. A., Yi, J., & Nycum, L. R. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.0505 · Cited by 1,384
The Concept of Synthetic Lethality in the Context of Anticancer Therapy
Kaelin, W. G. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1691 · Cited by 1,379
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
Bowtell, D. D., Böhm, S., Ahmed, A. A., Aspuria, P.-J., Bast, R. C., Beral, V., Berek, J. S., Birrer, M. J., Blagden, S., Bookman, M. A., et al. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4019 · Cited by 1,367
Matulonis, U. A., Sood, A. K., Fallowfield, L., Howitt, B. E., Sehouli, J., & Karlan, B. Y. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.61 · Cited by 1,362
The biology of ovarian cancer: new opportunities for translation
Bast, R. C., Hennessy, B., & Mills, G. B. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2644 · Cited by 1,358
Alberts, D. S., Liu, P. Y., Hannigan, E. V., O'Toole, R., Williams, S. D., Young, J. A., Franklin, E. W., Clarke-Pearson, D. L., Malviya, V. K., DuBeshter, B., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199612263352603 · Cited by 1,228
Shih, I.-M., & Kurman, R. J. (2004) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)63708-x · Cited by 1,206
INCESSANT OVULATION—A FACTOR IN OVARIAN NEOPLASIA ?
Fathalla, M. F. (1971) · The Lancet · doi:10.1016/s0140-6736(71)92335-x · Cited by 1,119
Gelmon, K. A., Tischkowitz, M., Mackay, H., Swenerton, K., Robidoux, A., Tonkin, K., Hirte, H., Huntsman, D., Clemons, M., Gilks, B., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70214-5 · Cited by 1,117
Kindelberger, D. W., Lee, Y., Miron, A., Hirsch, M. S., Feltmate, C., Medeiros, F., Callahan, M. J., Garner, E. O., Gordon, R. W., Birch, C., et al. (2007) · The American Journal of Surgical Pathology · doi:10.1097/01.pas.0000213335.40358.47 · Cited by 1,113
du Bois, A. (2003) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/djg036 · Cited by 1,113
McGuire, W. P., Rowinsky, E. K., Rosenshein, N. B., Grumbine, F. C., Ettinger, D. S., Armstrong, D. K., & Donehower, R. C. (1989) · Annals of Internal Medicine · doi:10.7326/0003-4819-111-4-273 · Cited by 1,100
Markman, M., Bundy, B. N., Alberts, D. S., Fowler, J. M., Clark-Pearson, D. L., Carson, L. F., Wadler, S., & Sickel, J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.4.1001 · Cited by 1,080
Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer—Shifting the paradigm
Kurman, R. J., & Shih, I.-M. (2011) · Human Pathology · doi:10.1016/j.humpath.2011.03.003 · Cited by 1,073
Jacobs, I. J., Menon, U., Ryan, A., Gentry-Maharaj, A., Burnell, M., Kalsi, J. K., Amso, N. N., Apostolidou, S., Benjamin, E., Cruickshank, D., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01224-6 · Cited by 1,048 · cited 1×
“A recent trial evaluating the utility of transvaginal ultrasonography in combination with serum CA125 levels demonstrated some promise in terms of early detection but failed to improve patient outcomes [61,62].”
BackgroundFong, P. C., Yap, T. A., Boss, D. S., Carden, C. P., Mergui-Roelvink, M., Gourley, C., De Greve, J., Lubinski, J., Shanley, S., Messiou, C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.9589 · Cited by 1,010
Epidemiology of epithelial ovarian cancer
Webb, P. M., & Jordan, S. J. (2017) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2016.08.006 · Cited by 995
The Dualistic Model of Ovarian Carcinogenesis
Kurman, R. J., & Shih, I.-M. (2016) · The American Journal of Pathology · doi:10.1016/j.ajpath.2015.11.011 · Cited by 923
Medeiros, F., Muto, M. G., Lee, Y., Elvin, J. A., Callahan, M. J., Feltmate, C., Garber, J. E., Cramer, D. W., & Crum, C. P. (2006) · American Journal of Surgical Pathology · doi:10.1097/01.pas.0000180854.28831.77 · Cited by 916
Oza, A. M., Cook, A. D., Pfisterer, J., Embleton, A., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G., Carey, M. S., Beale, P., Cervantes, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00086-8 · Cited by 875
Collaborative Group on Epidemiological Studies of Ovarian Cancer (2008) · The Lancet · doi:10.1016/s0140-6736(08)60167-1 · Cited by 822
Piek, J. M. J., van Diest, P. J., Zweemer, R. P., Jansen, J. W., Poort‐Keesom, R. J. J., Menko, F. H., Gille, J. J. P., Jongsma, A. P. M., Pals, G., Kenemans, P., et al. (2001) · The Journal of Pathology · doi:10.1002/path.1000 · Cited by 787
Inherited Mutations in Women With Ovarian Carcinoma
Norquist, B. M., Harrell, M. I., Brady, M. F., Walsh, T., Lee, M. K., Gulsuner, S., Bernards, S. S., Casadei, S., Yi, Q., Burger, R. A., et al. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.5495 · Cited by 769
Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial
Rustin, G. J., van der Burg, M. E., Griffin, C. L., Guthrie, D., Lamont, A., Jayson, G. C., Kristensen, G., Mediola, C., Coens, C., Qian, W., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61268-8 · Cited by 599
Perets, R., Wyant, G. A., Muto, K. W., Bijron, J. G., Poole, B. B., Chin, K. T., Chen, J. Y. H., Ohman, A. W., Stepule, C. D., Kwak, S., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.10.013 · Cited by 596
Liu, J. F., Barry, W. T., Birrer, M., Lee, J.-M., Buckanovich, R. J., Fleming, G. F., Rimel, B., Buss, M. K., Nattam, S., Hurteau, J., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70391-2 · Cited by 585
Prognostically relevant gene signatures of high-grade serous ovarian carcinoma
Verhaak, R. G. W., Tamayo, P., Yang, J.-Y., Hubbard, D., Zhang, H., Creighton, C. J., Fereday, S., Lawrence, M., Carter, S. L., Mermel, C. H., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci65833 · Cited by 569
Oza, A. M., Cibula, D., Benzaquen, A. O., Poole, C., Mathijssen, R. H. J., Sonke, G. S., Colombo, N., Špaček, J., Vuylsteke, P., Hirte, H., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71135-0 · Cited by 547
Ovarian Cancer Metastasis: Integrating insights from disparate model organisms
Naora, H., & Montell, D. J. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1611 · Cited by 538
Wentzensen, N., Poole, E. M., Trabert, B., White, E., Arslan, A. A., Patel, A. V., Setiawan, V. W., Visvanathan, K., Weiderpass, E., Adami, H.-O., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.66.8178 · Cited by 514
Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer
Phelan, C. M., Kuchenbaecker, K. B., Tyrer, J. P., Kar, S. P., Lawrenson, K., Winham, S. J., Dennis, J., Pirie, A., Riggan, M. J., Chornokur, G., et al. (2017) · Nature Genetics · doi:10.1038/ng.3826 · Cited by 502
Collaborative Group on Epidemiological Studies of Ovarian Cancer (2015) · The Lancet · doi:10.1016/s0140-6736(14)61687-1 · Cited by 472
Kaye, S. B., Lubinski, J., Matulonis, U., Ang, J. E., Gourley, C., Karlan, B. Y., Amnon, A., Bell-McGuinn, K. M., Chen, L.-M., Friedlander, M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.9215 · Cited by 470
Let-7 expression defines two differentiation stages of cancer
Shell, S., Park, S.-M., Radjabi, A. R., Schickel, R., Kistner, E. O., Jewell, D. A., Feig, C., Lengyel, E., & Peter, M. E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704372104 · Cited by 458
Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer
Ramus, S. J., Song, H., Dicks, E., Tyrer, J. P., Rosenthal, A. N., Intermaggio, M. P., Fraser, L., Gentry-Maharaj, A., Hayward, J., Philpott, S., et al. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv214 · Cited by 437
Chang, S.-J., Hodeib, M., Chang, J., & Bristow, R. E. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.05.040 · Cited by 433
Neijt, J. P., Engelholm, S. A., Tuxen, M. K., Sørensen, P. G., Hansen, M., Sessa, C., de Swart, C. A. M., Hirsch, F. R., Lund, B., & van Houwelingen, H. C. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.17.3084 · Cited by 428
Ovarian Cancer Cell Line Panel (OCCP): Clinical Importance of In Vitro Morphological Subtypes
Beaufort, C. M., Helmijr, J. C. A., Piskorz, A. M., Hoogstraat, M., Ruigrok-Ritstier, K., Besselink, N., Murtaza, M., van IJcken, W. F. J., Heine, A. A. J., Smid, M., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0103988 · Cited by 403
High-grade serous ovarian cancer arises from fallopian tube in a mouse model
Kim, J., Coffey, D. M., Creighton, C. J., Yu, Z., Hawkins, S. M., & Matzuk, M. M. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1117135109 · Cited by 398
Prognostic and Therapeutic Relevance of Molecular Subtypes in High-Grade Serous Ovarian Cancer
Konecny, G. E., Wang, C., Hamidi, H., Winterhoff, B., Kalli, K. R., Dering, J., Ginther, C., Chen, H.-W., Dowdy, S., Cliby, W., et al. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju249 · Cited by 398
Pignata, S., Scambia, G., Katsaros, D., Gallo, C., Pujade-Lauraine, E., De Placido, S., Bologna, A., Weber, B., Raspagliesi, F., Panici, P. B., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70049-x · Cited by 389
Kuhn, E., Kurman, R. J., Vang, R., Sehdev, A. S., Han, G., Soslow, R., Wang, T., & Shih, I. (2012) · The Journal of Pathology · doi:10.1002/path.3023 · Cited by 387
Cheon, D.-J., Tong, Y., Sim, M.-S., Dering, J., Berel, D., Cui, X., Lester, J., Beach, J. A., Tighiouart, M., Walts, A. E., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1256 · Cited by 373
Thigpen, J. T., Blessing, J. A., Ball, H., Hummel, S. J., & Barrett, R. J. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.9.1748 · Cited by 372
Can advanced-stage ovarian cancer be cured?
Narod, S. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.224 · Cited by 369
Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer
Chan, J. K., Brady, M. F., Penson, R. T., Huang, H., Birrer, M. J., Walker, J. L., DiSilvestro, P. A., Rubin, S. C., Martin, L. P., Davidson, S. A., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1505067 · Cited by 367
2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer
Mutch, D. G., & Prat, J. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.04.013 · Cited by 358
Treatment of recurrent ovarian cancer
Pignata, S., C Cecere, S., Du Bois, A., Harter, P., & Heitz, F. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx441 · Cited by 338
Incorporation of Pazopanib in Maintenance Therapy of Ovarian Cancer
du Bois, A., Floquet, A., Kim, J.-W., Rau, J., del Campo, J. M., Friedlander, M., Pignata, S., Fujiwara, K., Vergote, I., Colombo, N., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.55.7348 · Cited by 328
Song, H., Dicks, E., Ramus, S. J., Tyrer, J. P., Intermaggio, M. P., Hayward, J., Edlund, C. K., Conti, D., Harrington, P., Fraser, L., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.2408 · Cited by 328
Alberts, D. S., Green, S., Hannigan, E. V., O’Toole, R. V., Stock-Novack, D., Anderson, P., Surwit, E. A., Malvlya, V. K., Nahhas, W. A., & Jolles, C. J. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.5.706 · Cited by 317
Marquez, R. T., Baggerly, K. A., Patterson, A. P., Liu, J., Broaddus, R., Frumovitz, M., Atkinson, E. N., Smith, D. I., Hartmann, L., Fishman, D., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2509 · Cited by 308
Cheng, W., Liu, J., Yoshida, H., Rosen, D., & Naora, H. (2005) · Nature Medicine · doi:10.1038/nm1230 · Cited by 305
Mechanisms of human tumor metastasis studied in patients with peritoneovenous shunts.
Tarin, D., Price, J. E., Kettlewell, M. G. W., Souter, R. G., Ac, V., & Crossley, B. (1984) · PubMed · Cited by 303
Matulonis, U. A., Berlin, S., Ivy, P., Tyburski, K., Krasner, C., Zarwan, C., Berkenblit, A., Campos, S., Horowitz, N., Cannistra, S. A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.2777 · Cited by 302
The disparate origins of ovarian cancers: pathogenesis and prevention strategies
Karnezis, A. N., Cho, K. R., Gilks, C. B., Pearce, C. L., & Huntsman, D. G. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.113 · Cited by 300
Integrated analysis of germline and somatic variants in ovarian cancer
Kanchi, K. L., Johnson, K. J., Lu, C., McLellan, M. D., Leiserson, M. D. M., Wendl, M. C., Zhang, Q., Koboldt, D. C., Xie, M., Kandoth, C., et al. (2014) · Nature Communications · doi:10.1038/ncomms4156 · Cited by 296
Shaw, T. J., Senterman, M. K., Dawson, K., Crane, C. A., & Vanderhyden, B. C. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.08.013 · Cited by 278
Characterization and properties of nine human ovarian adenocarcinoma cell lines.
Langdon, S. P., Lawrie, S. S., Hay, F. G., Hawkes, M. M., McDonald, A. W., Hayward, I. P., Schol, D. J., Hilgers, J., Leonard, R. C., & Smyth, J. F. (1988) · PubMed · Cited by 269
Dubeau, L. (1999) · Gynecologic Oncology · doi:10.1006/gyno.1998.5275 · Cited by 262
Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma
Soslow, R. A., Han, G., Park, K. J., Garg, K., Olvera, N., Spriggs, D. R., Kauff, N. D., & Levine, D. A. (2012) · Modern Pathology · doi:10.1038/modpathol.2011.183 · Cited by 262
Riopel, M. A., Ronnett, B. M., & Kurman, R. J. (1999) · The American Journal of Surgical Pathology · doi:10.1097/00000478-199906000-00001 · Cited by 258
Horowitz, N. S., Miller, A., Rungruang, B., Richard, S. D., Rodriguez, N., Bookman, M. A., Hamilton, C. A., Krivak, T. C., & Maxwell, G. L. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.3106 · Cited by 252
Kenny, H. A., Krausz, T., Yamada, S. D., & Lengyel, E. (2007) · International Journal of Cancer · doi:10.1002/ijc.22874 · Cited by 243
Wang, Y., Li, L., Douville, C., Cohen, J. D., Yen, T.-T., Kinde, I., Sundfelt, K., Kjær, S. K., Hruban, R. H., Shih, I.-M., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aap8793 · Cited by 243
Self-citationSociety of Gynecologic Oncology recommendations for the prevention of ovarian cancer
Walker, J. L., Powell, C. B., Chen, L., Carter, J., Bae Jump, V. L., Parker, L. P., Borowsky, M. E., & Gibb, R. K. (2015) · Cancer · doi:10.1002/cncr.29321 · Cited by 241
A systematic review and meta‐analysis of family history and risk of ovarian cancer
Stratton, J. F., Pharoah, P., Smith, S. K., Easton, D., & Ponder, B. A. J. (1998) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.1998.tb10148.x · Cited by 239
Ledermann, J. A., Embleton, A. C., Raja, F., Perren, T. J., Jayson, G. C., Rustin, G. J. S., Kaye, S. B., Hirte, H., Eisenhauer, E., Vaughan, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01167-8 · Cited by 237
Kato, N., Sasou, S.-I., & Motoyama, T. (2006) · Modern Pathology · doi:10.1038/modpathol.3800492 · Cited by 226
In vivo tumor growth of high-grade serous ovarian cancer cell lines
Mitra, A. K., Davis, D. A., Tomar, S., Roy, L., Gurler, H., Xie, J., Lantvit, D. D., Cardenas, H., Fang, F., Liu, Y., et al. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.05.040 · Cited by 213
Coscia, F., Watters, K. M., Curtis, M., Eckert, M. A., Chiang, C. Y., Tyanova, S., Montag, A., Lastra, R. R., Lengyel, E., & Mann, M. (2016) · Nature Communications · doi:10.1038/ncomms12645 · Cited by 212
Epithelial ovarian cancer experimental models
Lengyel, E., Burdette, J. E., Kenny, H. A., Matei, D., Pilrose, J., Haluska, P., Nephew, K. P., Hales, D. B., & Stack, M. S. (2014) · Oncogene · doi:10.1038/onc.2013.321 · Cited by 208
Chang, S.-J., Bristow, R. E., & Ryu, H.-S. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2446-8 · Cited by 204
Menon, U., Ryan, A., Kalsi, J., Gentry-Maharaj, A., Dawnay, A., Habib, M., Apostolidou, S., Singh, N., Benjamin, E., Burnell, M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.4945 · Cited by 196
Risk Prediction for Late-Stage Ovarian Cancer by Meta-analysis of 1525 Patient Samples
Riester, M., Wei, W., Waldron, L., Culhane, A. C., Trippa, L., Oliva, E., Kim, S.-H., Michor, F., Huttenhower, C., Parmigiani, G., et al. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju048 · Cited by 195
Francis, P. A., Rowinsky, E. K., Schneider, J., Hakes, T. B., Hoskins, W. J., & Markman, M. M. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.12.2961 · Cited by 191
Testa, U., Petrucci, E., Pasquini, L., Castelli, G., & Pelosi, E. (2018) · Medicines · doi:10.3390/medicines5010016 · Cited by 188
Surgical cytoreduction for recurrent epithelial ovarian cancer
Al Rawahi, T., Lopes, A. D., Bristow, R. E., Bryant, A., Elattar, A., Chattopadhyay, S., & Galaal, K. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008765.pub3 · Cited by 178
Vang, R., Levine, D. A., Soslow, R. A., Zaloudek, C., Shih, I.-M., & Kurman, R. J. (2016) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000000207 · Cited by 170
Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies
Sieh, W., Salvador, S., McGuire, V., Weber, R. P., Terry, K. L., Rossing, M. A., Risch, H., Wu, A. H., Webb, P. M., Moysich, K., et al. (2013) · International Journal of Epidemiology · doi:10.1093/ije/dyt042 · Cited by 170
TP53 mutations in epithelial ovarian cancer
Zhang, Y., Cao, L., Nguyen, D., & Lu, H. (2016) · Translational Cancer Research · doi:10.21037/tcr.2016.08.40 · Cited by 170
The Changing View of High-Grade Serous Ovarian Cancer
Berns, E. M. J. J., & Bowtell, D. D. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3911 · Cited by 169
Kang, J., D’Andrea, A. D., & Kozono, D. (2012) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djs177 · Cited by 167
Candido-dos-Reis, F. J., Song, H., Goode, E. L., Cunningham, J. M., Fridley, B. L., Larson, M. C., Alsop, K., Dicks, E., Harrington, P., Ramus, S. J., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2497 · Cited by 161
Breastfeeding and ovarian cancer risk: a meta-analysis of epidemiologic studies
Luan, N.-N., Wu, Q.-J., Gong, T.-T., Vogtmann, E., Wang, Y.-L., & Lin, B. (2013) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.113.062794 · Cited by 159
Age at menarche and risk of ovarian cancer: A meta‐analysis of epidemiological studies
Gong, T., Wu, Q., Vogtmann, E., Lin, B., & Wang, Y. (2012) · International Journal of Cancer · doi:10.1002/ijc.27952 · Cited by 157
Gilbert, L., Basso, O., Sampalis, J. S., Karp, I., Martins, C., Feng, J., Piedimonte, S., Quintal, L., Ramanakumar, A. V., TAKEFMAN, J. E., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70333-3 · Cited by 155
Kuhn, E., Meeker, A. K., Wang, T., Sehdev, A. E. S., Kurman, R. J., & Shih, I. (2010) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3181dcede7 · Cited by 154
Clinical Characteristics of Ovarian Cancer Classified by BRCA1, BRCA2 and RAD51C Status
Cunningham, J. M., Cicek, M. S., Larson, N. B., Davila, J. I., Wang, C., Larson, M. C., Song, H., Dicks, E., Harrington, P. A., Wick, M. J., et al. (2014) · Scientific Reports · doi:10.1038/srep04026 · Cited by 152
Veras, E. F. T., Mao, T., Ayhan, A., Ueda, S. M., Lai, H. C., Hayran, M., Shih, I., & Kurman, R. J. (2009) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e31819c4271 · Cited by 151
Sherman‐Baust, C. A., Kuhn, E., Valle, B. L., Shih, I., Kurman, R. J., Wang, T., Amano, T., Ko, M. S. H., Miyoshi, I., Araki, Y., et al. (2014) · The Journal of Pathology · doi:10.1002/path.4353 · Cited by 147
Ovarian Cancer is an Imported Disease: Fact or Fiction?
Kuhn, E., Kurman, R. J., & Shih, I. (2012) · Current Obstetrics and Gynecology Reports · doi:10.1007/s13669-011-0004-1 · Cited by 127
Ketabi, Z., Bartuma, K., Bernstein, I., Malander, S., Grönberg, H., Björck, E., Holck, S., & Nilbert, M. C. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.02.010 · Cited by 125
Cancers in Australia in 2010 attributable to modifiable factors: summary and conclusions
Whiteman, D. C., Webb, P. M., Green, A. C., Neale, R. Ε., Fritschi, L., Bain, C. J., Parkin, D. M., Wilson, L. F., Olsen, C. M., Nagle, C. M., et al. (2015) · Australian and New Zealand Journal of Public Health · doi:10.1111/1753-6405.12471 · Cited by 121
Dobbin, Z. C., Katre, A. A., Steg, A. D., Erickson, B. K., Shah, M. M., Alvarez, R. D., Conner, M., Schneider, D. A., Chen, D., & Landen, C. N. (2014) · Oncotarget · doi:10.18632/oncotarget.2373 · Cited by 120
Cancerous ovarian stem cells: Obscure targets for therapy but relevant to chemoresistance
Ahmed, N., Abubaker, K., Findlay, J. K., & Quinn, M. A. (2012) · Journal of Cellular Biochemistry · doi:10.1002/jcb.24317 · Cited by 113
Martins, F. C., de Santiago, I., Trinh, A. C., Xian, J., Guo, A., Sayal, K., Jimenez‐Liñan, M., Deen, S., Driver, K. E., Mack, M. L., et al. (2014) · Genome biology · doi:10.1186/s13059-014-0526-8 · Cited by 108
Huang, J., Zhang, L., Greshock, J. D., Colligon, T. A., Wang, Y., Ward, R., Katsaros, D., Lassus, H. J., Bützow, R. C., Godwin, A. K., et al. (2011) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20883 · Cited by 106
HMGA2: A biomarker significantly overexpressed in high-grade ovarian serous carcinoma
Mahajan, A., Liu, Z., Gellert, L. L., Zou, X., Yang, G., Lee, P., Yang, X. J., & Wei, J. (2010) · Modern Pathology · doi:10.1038/modpathol.2010.49 · Cited by 105
Bookman, M. A., Greer, B. E., & Ozols, R. F. (2003) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2003.13602.x · Cited by 103
High‐grade serous carcinomas arise in the mouse oviduct via defects linked to the human disease
Zhai, Y., WU, R. T., Kuick, R. D., Sessine, M. S., Schulman, S., Green, M., Fearon, E. R., & Cho, K. R. (2017) · The Journal of Pathology · doi:10.1002/path.4927 · Cited by 99
Murakami, R., Matsumura, N., Mandai, M., Yoshihara, K., Tanabe, H., Nakai, H., Yamanoi, K., Abiko, K., Yoshioka, Y., Hamanishi, J., et al. (2016) · American Journal Of Pathology · doi:10.1016/j.ajpath.2015.12.029 · Cited by 97
Wang, C., Armasu, S. M., Kalli, K. R., Maurer, M. J., Heinzen, E. P., Keeney, G. L., Cliby, W. A., Oberg, A. L., Kaufmann, S. H., & Goode, E. L. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0246 · Cited by 91
Brachova, P., Mueting, S. R., Carlson, M. J., Goodheart, M. J., Button, A. M., Mott, S. L., Dai, D., Thiel, K. W., Devor, E. J., & Leslie, K. K. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2747 · Cited by 89
Beyond genomics: Critical evaluation of cell line utility for ovarian cancer research
Elias, K. M., Emori, M. M., Papp, E., MacDuffie, E., Konecny, G. E., Velculescu, V. E., & Drapkin, R. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.08.017 · Cited by 87
Kuhn, E., Wang, T., Doberstein, K., Bahadirli-Talbott, A., Ayhan, A., Sehdev, A. E. S., Drapkin, R., Kurman, R. J., & Shih, I. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.101 · Cited by 87
Morrison, J. C., Blanco, L. Z., Vang, R., & Ronnett, B. M. (2014) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000000352 · Cited by 84
Hirte, H. W., Lheureux, S., Fleming, G. F., Sugimoto, A. K., Morgan, R. J., Biagi, J. J., Wang, L., McGill, S., Ivy, S. P., & Oza, A. M. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.04.009 · Cited by 80
Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment
Papa, A., Caruso, D., Strudel, M., Tomao, F., & Tomao, F. (2016) · Journal of Translational Medicine · doi:10.1186/s12967-016-1027-1 · Cited by 80
Auersperg, N. (2013) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0b013e3182800ad5 · Cited by 77
Létourneau, I. J., Quinn, M. C. J., Wang, L.-L., Portelance, L., Caceres, K., Cyr, L., Delvoye, N., Meunier, L., de Ladurantaye, M., Shen, Z. Z., et al. (2012) · BMC Cancer · doi:10.1186/1471-2407-12-379 · Cited by 75
In vitro and in vivo correlates of physiological and neoplastic human Fallopian tube stem cells
Yamamoto, Y., Ning, G., Howitt, B. E., Mehra, K. K., Wu, L., Wang, X., Yue, H., Kern, F., Wei, T. S., Zhang, T., et al. (2015) · The Journal of Pathology · doi:10.1002/path.4649 · Cited by 75
Identification of Quiescent, Stem-Like Cells in the Distal Female Reproductive Tract
Wang, Y., Sacchetti, A., van Dijk, M. R., van der Zee, M., van der Horst, P. H., Joosten, R., Burger, C. W., Grootegoed, J. A., Blok, L. J., & Fodde, R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040691 · Cited by 71
McGrail, D. J., Lin, C. C.-J., Garnett, J., Liu, Q., Mo, W., Dai, H., Lu, Y., Yu, Q., Ju, Z., Yin, J., et al. (2017) · npj Systems Biology and Applications · doi:10.1038/s41540-017-0011-6 · Cited by 64
Cells of origin of ovarian cancer: ovarian surface epithelium or fallopian tube?
Klotz, D. M., & Wimberger, P. (2017) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-017-4529-z · Cited by 59
Location of Mutation in BRCA2 Gene and Survival in Patients with Ovarian Cancer
Labidi‐Galy, S. I., Olivier, T., Rodrigues, M. J., Ferraioli, D., Derbel, O., Bodmer, A., Petignat, P., Rak, B., Chopin, N., Trédan, O., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2136 · Cited by 59
Monk, B. J., & Chan, J. K. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx451 · Cited by 53
Surgical cytoreduction for recurrent epithelial ovarian cancer
Rawahi, T. A., Galaal, K. A., Naik, R., Bristow, R. E., & Bryant, A. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008765.pub2 · Cited by 53
CDKN2D-WDFY2 Is a Cancer-Specific Fusion Gene Recurrent in High-Grade Serous Ovarian Carcinoma
Kannan, K., Coarfa, C., Rajapakshe, K., Hawkins, S. M., Matzuk, M. M., Milosavljevic, A., & Yen, L. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004216 · Cited by 49
In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene
Dunn, G. P., Cheung, H. W., Agarwalla, P. K., Thomas, S. R., Zektser, Y. A., Karst, A. M., Boehm, J. S., Weir, B. A., Berlin, A. M., Zou, L., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1311909111 · Cited by 46
The value of PAX8 and WT1 molecules in ovarian cancer diagnosis.
Liliac, L., Carcangiu, M. L., Canevari, S., et al. (2013) · PubMed · Cited by 43
Walker, J. L., Brady, M. F., DiSilvestro, P., Fujiwara, K., Ds, A., Zheng, W., Tewari, K. S., Cohn, D. E., Powell, M. A., Le, L. V., et al. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.04.535 · Cited by 43
Delaney, J. R., Patel, C. B., Willis, K. T., Haghighiabyaneh, M., Axelrod, J. L., Tancioni, I., Lü, D., Bapat, J., Young, S., Cadassou, O., et al. (2017) · Nature Communications · doi:10.1038/ncomms14423 · Cited by 41
Optimizing primary chemotherapy in ovarian cancer
Markman, M. M. (2003) · Hematology/Oncology Clinics of North America · doi:10.1016/s0889-8588(03)00058-3 · Cited by 39
The Prognostic 97 Chemoresponse Gene Signature in Ovarian Cancer
Matondo, A., Jo, Y. H., Shahid, M., Choi, T. G., Nguyen, M. N., Nguyen, N. N. Y., Akter, S., Kang, I., Ha, J., Maeng, C. H., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-08766-5 · Cited by 33
Zivanovic, O., Sima, C. S., Iasonos, A. E., Bell‐McGuinn, K. M., Sabbatini, P. J., Leitão, M. M., Levine, D. A., Gardner, G. J., Barakat, R. R., & Dennis, S. (2009) · Gynecologic Oncology · doi:10.1016/j.ygyno.2009.06.038 · Cited by 32
Stark, D., Cook, A. D., Brown, J. M., Brundage, M., Embleton-Thirsk, A., Kaplan, R. S., Raja, F. A., Swart, A. M., Velikova, G., Qian, W., et al. (2017) · Cancer · doi:10.1002/cncr.30657 · Cited by 28
Survival of patients with structurally-groupedTP53mutations in ovarian and breast cancers
Seagle, B.-L. L., Eng, K. H., Dandapani, M., Yeh, J. Y., Odunsi, K. O., & Shahabi, S. (2015) · Oncotarget · doi:10.18632/oncotarget.4080 · Cited by 26
Eoh, K. J., Chung, Y. S., Lee, S. H., Park, S., Kim, H. J., Yang, W., Lee, I. O., Lee, J., Cho, H., Chay, D. B., et al. (2017) · Cancer Research and Treatment · doi:10.4143/crt.2017.181 · Cited by 25
Bookman, M. A., Greer, B. E., & Ozols, R. F. (2003) · International Journal of Gynecological Cancer · doi:10.1111/j.1525-1438.2003.13362.x · Cited by 24
Rzepecka, I. K., Szafron, L. M., Styś, A., Bujko, M., Plisiecka-Hałasa, J., Mądry, R., Osuch, B., Markowska, J., Bidziński, M., & Kupryjańczyk, J. (2012) · Cancer Genetics · doi:10.1016/j.cancergen.2011.12.005 · Cited by 23
Liu, J. F., Barry, W. T., Birrer, M. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.15_suppl.5535 · Cited by 14
Ovarian Cancer Research in the Post Genomic Era — Challenges and Opportunities
Goyeneche, A. A., & Telleria, C. M. (2016) · InTech eBooks · doi:10.5772/60600 · Cited by 3
Self-citation
Metadata
- Authors
- Lisio, M.-A., Fu, L., Goyeneche, A., Gao, Z.-H., & Telleria, C.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-02-22
- Volume
- 20
- Issue
- 4
- Pages
- 952
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2917476978
- Cited by
- 680
- References
- 157
- FWCI
- 60.31
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.